Last reviewed · How we verify
Triple Negative Breast Cancer — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Azd5363 | azd5363 | Pfizer | phosphatidylinositol 3-kinase (PI3K) inhibitor | AKT |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Triple Negative Breast Cancer
- Pfizer · 1 drug in Triple Negative Breast Cancer
- Pfizer Inc. · 1 drug in Triple Negative Breast Cancer
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Triple Negative Breast Cancer:
- Triple Negative Breast Cancer treatment updates — RSS
- Triple Negative Breast Cancer treatment updates — Atom
- Triple Negative Breast Cancer treatment updates — JSON
Cite this brief
Drug Landscape (2026). Triple Negative Breast Cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/triple-negative-breast-cancer. Accessed 2026-06-10.
Related
- Triple Negative Breast Cancer full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing